GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025
Geneva, Switzerland, 10 June 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an extraordinary shareholders’ meeting on June 30, 2025. As previously disclosed, GeNeuro is subject to a definitive debt-restructuring moratorium granted by the Geneva […]